The chemotherapy of rodent malaria. LXIII. Drug combinations to impede the selection of drug resistance, part 6: the potential value of chlorproguanil and dapsone in combination, and with the addition of artesunate

REFERENCES

• Alloueche, A., Bailey, W., Barton, S., Bwika, J., Chimpeni, P., Falade, C. O., Fehintola, F. A., Horton, J., Jaffar, S., Kanyok, T., Kremsner, P. G., Kublin, J. G., Lang, T., Missinou, M. A., Mkandala, C., Oduola, A. M. J., Premji, Z., Robertson, L., Sowunmi, A., Ward, S. A. & Winstanley, P. A. (2004). Comparison of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomised controlled trial. Lancet, 363, 1843–1848.
   PubMed Web of Science ®Google Scholar
• Amukoye, E., Winstanley, P. A., Watkins, W. M., Snow, R W., Hatcher, J., Mosobo, M., Ngumbao, E., Lowe, B., Ton, M., Minyiri, G. & Marsh, K. (1997). Chlorproguanil-dapsone: effective treatment for uncomplicated falciparum malaria. Antimicrobial Agents and Chemotherapy, 41, 2261–2264.
   PubMed Web of Science ®Google Scholar
• Anon. (2004). Artesunate combinations for treatment of malaria: meta-analysis. Lancet, 363, 9–17.
   PubMed Web of Science ®Google Scholar
• Attaran, A., Barnes, K. I., Curtis, C., d'Alessandro, U., Fanello, C. I., Galinski, M. R, Kokwam, G., Looareesuwan, S., Makanga, M., Mutabingwa, T. K., Talisuna, A., Trape, J.-F. & Watkins, W. M. (2004). WHO, the Global Fund, and medical malpractice in malaria treatment. Lancet, 363, 237-240.
   Google Scholar
• Black, R. H. (1973). Malaria in the Australian army in South Vietnam. Successful use of a proguanil-dapsone combination for chemoprophylmds of chlor-oquine-resistant falciparum malaria. Medical Journal of Australia, 1, 1265–1270.
   PubMed Web of Science ®Google Scholar
• Chin. W., Contacos, P. G., Coamey, G. R., Jeter, M. H. & Alpert, E. (1967). Evaluation of CI-564, a 1: 1 mixture of cycloguanil pamoate (CI-501) and 4,4'-diacetylaminodiphenylsulfone (CI-556), against multiresistant falciparum malaria. American Journal of Tropical Medicine and Hygiene, 16, 580–584.
   PubMed Web of Science ®Google Scholar
• Curtis, J., Duraisingh, M. T. & Warhurst, D. C. (1998). In vivo selection for a specific genotype of dihydropteroate synthetase of Plasmodium falci-parum by pyrimethamine-sulfadoxine but not chlorproguanil-dapsone treatment. Journal of Infectious Diseases, 177, 1429–1432.
   PubMed Web of Science ®Google Scholar
• Curtis, J., Maxwell, C. A., Msuya, F. H. M., Mkongewa, S., Alloueche, A. & Warhurst, D. C. (2002). Mutations in dhfr in Plasmodium falciparum infections selected by chlorproguanil-dapsone treat-ment. Journal of Infectious Diseases, 186, 1861-1864. Elslager, E. F. (1969). Progress in malaria chemother-apy. Part 1. Repository antimalarial drugs. Progress in Drug Research, 13, 170–216.
   Google Scholar
• Fidock, D. A., Nomura, T. & Wellems, T. E. (1998). Cycloguanil and its parent compound proguanil demonstrate distinct activities against Plasmodium falciparum malaria parasites transformed with human dihydrofolate reductase. Molecular Pharmacology, 54, 1140–1147.
   PubMed Web of Science ®Google Scholar
• Hastings, I. M., Watkins, W. M. & White, N. J. (2002). The evolution of drug-resistant malaria: the role of drug elimination half-life. Philosophical Transactions of the Royal Society of London, Series B, 357, 505-519. Hill, J. (1963). Chemotherapy of malaria. Part 2: The antimalarial drugs. In Experimental Malaria, Vol. 1, eds Schnitzer, R. J. & Hawking, F. pp. 513-601. London: Academic Press.
   Google Scholar
• Lang, T. & Greenwood, B. (2002). The development of Lapdap, an affordable new treatment for malaria. Lancet Infectious Diseases, 3, 162–168.
   Web of Science ®Google Scholar
• Mutabingwa, T. K., Maxwell, C. A., Sia, I. G., Msuya, F. H. M., Mkongewa, S., Vannithone, S., Curtis, J. & Curtis, C. F. (2001). A trial of proguanil-dapsone in comparison with sulfadoxine-pyrimethamine for the clearance of Plasmodium falciparum infections in Tanzania. Transactions of the Royal Society of Tropical Medicine and Hygiene, 95, 433–438.
   PubMed Web of Science ®Google Scholar
• Nzila, A. M., Nduati, E., Mberu, E. K., Sibley, C. H., Monks, S. A., Winstanley, P. A. & Watkins, W. M. (2000). Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate pyrimethamine/sulfadoxine com-pared with the shorter-acting chlorproguanil/dpasone on Kenyan Plasmodium falciparum. Journal of Infectious Diseases, 181, 2023–2028.
   PubMed Web of Science ®Google Scholar
• Peters, W. (1968). The chemotherapy of rodent malaria, VII. The action of some sulphonamides alone or with folic reductase inhibitors against malaria vectors and parasites, part 2: schizontocidal action in the albino mouse. Annals of Tropical Medicine and Parasitology, 62, 488–494.
   Google Scholar
• Peters, W. (1970a). Chemotherapy and Drug Resistance in Malaria. London: Academic Press.
   Google Scholar
• Peters, W. (1970b). The chemotherapy of rodent malaria, X. Dynamics of drug resistance, part 2: acquisition and loss of chloroquine resistance in Plasmodium berghei observed by continuous bioassay. Annals of Tropical Medicine and Parasitology, 64, 25–40.
   PubMed Web of Science ®Google Scholar
• Peters, W. (1987). Chemotherapy and Drug Resistance in Malaria, 2nd Edn. London: Academic Press.
   Google Scholar
• Peters, W. & Robinson, B. L. (1998). Malaria. In Handbook of Animal Models for Infection. Section IV. Parasitic Infection Models, eds Zak, O. & Sande, M. pp. 756-771. London: Academic Press.
   Google Scholar
• Peters, W. & Robinson, B. L. (1999). The chemotherapy of rodent malaria. LVI. Studies on the develop-ment of resistance to natural and synthetic endoperoxides. Annals of Tropical Medicine and Parasitology, 93, 325–339.
   PubMed Web of Science ®Google Scholar
• Peters, W. & Robinson, B. L. (2000). The chemotherapy of rodent malaria. LVIII. Drug combinations to impede the selection of drug resistance, part 2: the new generation - artemisinin or artesunate with long-acting blood schizontocides. Annals of Tropical Medicine and Parasitology, 94, 23–35.
   PubMed Web of Science ®Google Scholar
• Rieckmann, K. H. (1967). A new repository antimalarial, CI-564 used in a field trial in New Guinea. Transactions of the Royal Society of Tropical Medicine and Hygiene, 61, 189–198.
   PubMed Web of Science ®Google Scholar
• Sibley, C. H., Hyde, J. E., Sims, P. F. G., Plowe, C. V., Kublin, J. G., Mberu, E. K., Cowman, A. F., Winstanley, P. A., Watkins, W. M. & Nzila, A. M. (2001). Pyrimetharnine-sulfadoxine resistance in Plasmodium falciparum: what next? Trends in Parasitology, 17,582–588.
   PubMed Web of Science ®Google Scholar
• Smith, C. C., Ihrig, J. & Menne, R (1961). Antimalarial activity and metabolism of biguanides. I. Metabolism of chlorguanide and chlorguanide triazine in rhesus monkeys and man. American Journal of Tropical Medicine and Hygiene, 10, 694–703.
   Web of Science ®Google Scholar
• Stewart, L. B., Peters, W. & Robinson, B. L. (2004). The chemotherapy of rodent malaria. LXII. Drug combinations to impede the selection of drug resistance, part 5: rates of development of resistance to some inhibitors of folate metabolism and to artesunate. Annals of Tropical Medicine and Parasitology, 98, 763–783.
   PubMed Web of Science ®Google Scholar
• Sub, J., Chimpeni, P., Hatcher, J., Kublin, J. G., Plowe, C. V., Molyneux, M. E., Marsh, K., Taylor, T. E., Watkins, W. M. & Winstanley, P. A. (2002). Chlorproguanil-dapsone versus sulfadoxine-pyri-methamine for sequential episodes of uncomplicated falciparum malaria in Kenya and Malawi: a rando-mised clinical trial. Lancet, 360, 1136–1143.
   Google Scholar
• Thompson, P. E., Bayles, A., Olszewski, B. & Waitz, J. A. (1965). Studies on a dihydrotriazine and a sulfone, alone and in combination, against Plasmodium berghei in mice. American Journal of Tropical Medicine and Hygiene, 14, 198–206.
   PubMed Web of Science ®Google Scholar
• Trape, J. F., Pison, G., Preziosi, C., Enel, A. D., du Lou, V., Delaunay, B., Samb, E., Lagarde, E., Molez, J. F. & Simondon, F. (1998). Impact of chloroquine resistance on malaria mortality. Compte Rendu de l'Académie des Sciences. Series3, Sciences de la Vie, 321, 689–697.
   Google Scholar
• Watkins, W. M., Sixsmith, D. G. & Chulay, J. D. (1984). The activity of proguanil and its metabolites, cycloguanil and p-chlorophenylbiguanide, against Plasmodium falciparum in vitro. Annals of Tropical Medicine and Parasitology, 78, 273–278.
   PubMed Web of Science ®Google Scholar
• Watkins, W. M., Brandling-Bennett, A. D., Nevill, C. G., Carter, J. Y., Boriga, D. A., Howells, R. E. & Koech, D. K. (1988). Chlorproguanil/dapsone for the treatment of non-severe Plasmodium falciparum malaria in Kenya: a pilot study. Transactions of the Royal Society of Tropical Medicine and Hygiene, 82, 398–403.
   PubMed Web of Science ®Google Scholar
• White, N. J. (1998). Preventing antimalarial drug resistance through combinations. Drug Resistance Updates, 1, 3–9.
   PubMed Web of Science ®Google Scholar
• White, N. J. & Pongtavornpinyo, W. (2003). The de novo selection of drug-resistant malaria parasites. Proceedings of the Royal Society of London, Series B, 270, 545–554.
   Web of Science ®Google Scholar
• White, N. J., Nosten, F., Looareesuwan, S., Watkins, W. M., Marsh, K., Snow, R. W., Kokwaro, G., Ouma, J., Hien, T. T., Molyneux, M. E., Taylor, T. E., Newbold, C. I., Ruebush II, T. K., Danis, M., Greenwood, B. M., Anderson, R. M. & Olliaro, P. (1999). Averting a malaria disaster. Lancet, 353, 1965–1967.
   PubMed Web of Science ®Google Scholar
• Wilairatana, P., Kyle, D. E., Looareesuwan, S., Chinwongprom, K., Amradee, S., White, N. J. & Watkins, W. M. (1997). Poor efficacy of antimalarial biguanide-dapsone combinations in the treatment of acute, uncomplicated, falciparum malaria in Thailand. Annals of Tropical Medicine and Parasitology, 91, 125–132.
   PubMed Web of Science ®Google Scholar
• Winstanley, P. A., Ward, S. A. & Snow, R. W. (2002). Clinical status and implications of antimalarial drug resistance. Microbes and Infection, 4,157–164.
   PubMed Web of Science ®Google Scholar
• World Health Organization (2003). Lapdap: a new antimalarial for Africa. TDR News, 70, 2.
   Google Scholar